세계 항고혈압제 시장 규모는 2023년 297억 달러에 달했습니다. 향후 IMARC Group은 2024-2032년 연평균 성장률(CAGR) 2.7%로 2032년 380억 달러에 달할 것으로 예상하고 있습니다. 고혈압 유병률 증가, CVD 환자 수 증가, 임상 연구 수 증가가 시장을 주도하는 주요 요인 중 하나입니다.
항고혈압제는 동맥벽에 대한 혈액의 힘을 증가시켜 심장병, 뇌졸중 및 기타 건강 문제의 위험을 증가시킬 수 있는 고혈압을 치료하는 데 사용됩니다. 일반적으로 이뇨제, 베타 차단제, 칼슘 길항제, 안지오텐신 전환효소(ACE) 억제제, 혈관 확장제로 구성됩니다. 혈관확장제는 혈관을 이완시키고 혈관 내 수분량을 감소시키며 혈관을 수축시키는 호르몬의 양을 감소시켜 혈관을 수축시키는 작용을 합니다. 또한 심장 박동을 늦추고 수축기 혈압을 건강하게 유지하여 수명을 연장하고 조기사망 위험을 최소화합니다. 현재 주요 기업들은 제품 포트폴리오를 확장하기 위해 이미다졸린, 모나테필, 중성 엔펩티데이즈 억제제를 도입하고 있습니다.
개개인의 고혈압과 고혈압의 급증은 전 세계적으로 항고혈압제 수요를 견인하는 주요 요인 중 하나입니다. 또한, 이러한 질환에 취약한 노인 인구의 증가는 시장에 긍정적인 영향을 미치고 있습니다. 또한, 좌식 생활 습관, 건강에 해로운 식습관, 높은 스트레스 수준, 당뇨병 및 비만으로 인해 심혈관질환(CVD)을 앓고 있는 환자가 증가하고 있는 것도 시장 성장을 촉진하고 있습니다. 이와는 별도로, 많은 국가의 정부 기관이 고혈압, 증상, 진단 및 치료에 대한 인식을 높이기 위해 캠페인을 시작하고 있습니다. 이는 고혈압의 새로운 치료법을 개발하기 위한 임상 연구 및 임상시험의 증가와 함께 시장 성장을 강화하고 있습니다. 또한, 의료비 증가로 인해 일반의약품(OTC)을 통한 고혈압 관련 질환 치료의 사용이 증가하고 있는 것도 시장 전망을 밝게 하고 있습니다. 이와 더불어, 소비자가 필요로 하는 용량에 따라 항고혈압제를 제공하는 온라인 소매 플랫폼이 증가하고 있습니다. 이는 제약 산업과 E-Commerce 산업의 괄목할 만한 성장과 함께 시장 성장을 촉진하고 있습니다. 또한, 고혈압 치료에 대한 재정적 지원을 제공하고 의료 비용을 최소화하는 건강 보험의 도입이 증가함에 따라 시장 성장을 촉진하고 있습니다.
The global antihypertensive drugs market size reached US$ 29.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 38.0 Billion by 2032, exhibiting a growth rate (CAGR) of 2.7% during 2024-2032. The increasing prevalence of hypertension, rising number of patients suffering from CVDs, and the growing number of clinical studies represent some of the key factors driving the market.
Antihypertensive drugs are utilized to treat hypertension wherein the force of blood against the walls of the arteries becomes high and can increase the risk of heart disease, stroke, and other health problems. They generally comprise diuretics, beta-blockers, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, and vasodilators. They work by relaxing the blood vessels, reducing the amount of fluid in the blood vessels, and decreasing the amount of hormones that cause blood vessels to constrict. They also slow down the heartbeat, maintain a healthy systolic BP, improve life expectancy, and minimize the risk of premature death. At present, key players are introducing imidazolines, monatepil, and neutral endopeptidase inhibitors to expand their product portfolio.
The surging prevalence of hypertension and high BP among individuals represents one of the major factors driving the demand for antihypertensive drugs around the world. Moreover, the growing geriatric population that is susceptible to developing these medical disorders is influencing the market positively. In addition, the increasing number of patients suffering from cardiovascular diseases (CVDs) on account of sedentary lifestyles, unhealthy dietary patterns, high-stress levels, diabetes, and obesity among the masses is favoring the growth of the market. Apart from this, governing agencies of numerous countries are initiating campaigns to spread awareness about the hypertension disorder, its symptoms, diagnosis, and treatment. This, coupled with the rising number of clinical studies and trials to develop new treatments for hypertension, is strengthening the growth of the market. Furthermore, the growing usage of over the counter (OTC) drugs to treat BP-related diseases on account of expanding healthcare costs is creating a positive outlook for the market. Besides this, there is a rise in the number of online retail platforms that offer antihypertensive drugs according to the dosage needed by the consumer. This, along with significant growth in the pharmaceutical and e-commerce industries, is propelling the growth of the market. Additionally, the increasing adoption of health insurance policies that provide financial assistance for hypertension treatment and minimize healthcare expenses is impelling the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global antihypertensive drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on therapeutic class, type and distribution channel.
Diuretics
ACE Inhibitors
Calcium Channel Blockers
Beta-adrenergic Blockers
Vasodilators
Others
The report has provided a detailed breakup and analysis of the antihypertensive drugs market based on the therapeutic class. This includes diuretics, ACE inhibitors, calcium channel blockers, beta-adrenergic blockers, vasodilators, and others. According to the report, calcium channel blockers represented the largest segment.
Primary Hypertension
Secondary Hypertension
A detailed breakup and analysis of the antihypertensive drugs market based on the type has also been provided in the report. This includes primary hypertension and secondary hypertension. According to the report, primary hypertension accounted for the largest market share.
Retail Pharmacy
Hospital Pharmacy
E-Commerce
The report has provided a detailed breakup and analysis of the antihypertensive drugs market based on the distribution channel. This includes retail pharmacy, hospital pharmacy, and e-commerce. According to the report, hospital pharmacy represented the largest segment.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for antihypertensive drugs. Some of the factors driving the North America antihypertensive drugs market included expansion of online pharmacies, government initiatives, product innovation, etc.
The report has also provided a comprehensive analysis of the competitive landscape in the global antihypertensive drugs market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include AstraZeneca, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Johnson & Johnson Services Inc., Lupin Pharmaceuticals Inc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.